Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter

IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

See all formats and pricing
More options …
Volume 57, Issue 9


The effect of DOAC-Stop on lupus anticoagulant testing in plasma samples of venous thromboembolism patients receiving direct oral anticoagulants

Michał ZąbczykORCID iD: https://orcid.org/0000-0003-1762-308X / Magdalena Kopytek
  • Institute of Cardiology, Jagiellonian University Medical College and John Paul II Hospital, Krakow, Poland
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Joanna Natorska
  • Institute of Cardiology, Jagiellonian University Medical College and John Paul II Hospital, Krakow, Poland
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Anetta Undas
  • Corresponding author
  • Institute of Cardiology, Jagiellonian University Medical College and John Paul II Hospital, Krakow, Poland
  • Faculty of Medicine and Health Sciences, Jan Kochanowski University, Kielce, Poland, Phone: +48-12-6143004, Fax: +48-12-6142120
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2019-02-14 | DOI: https://doi.org/10.1515/cclm-2018-1197



Direct oral anticoagulants (DOACs) cause false positive lupus anticoagulant (LA) results. We assessed the impact of DOAC-Stop, reversing in vitro effects of DOACs, on LA testing in anticoagulated patients.


We assessed 75 venous thromboembolism patients aged 44.5±14.6 years. Blood samples were collected 2–28 h since intake of DOACs, including 50 patients on rivaroxaban, 20 on dabigatran and five on apixaban. LA testing was performed at baseline and after DOAC-Stop treatment. Positive LA was defined as the normalized (patient/standard plasma clotting time) LA screening and screening (LA1)/confirmation (LA2) ratios exceeding 1.2.


LA diluted Russell’s viper venom time (dRVVT) normalized screening test revealed abnormal results in 73 (97.3%) and activated partial thromboplastin time (APTT)-LA in 49 (65.3%) patients. In six (8%) patients, antiphospholipid syndrome (APS) was diagnosed. dRVVT LA1/LA2 was abnormal in 35 (50.7%) patients taking DOACs. The APTT ratio was normal in all studied subjects. DOAC-Stop completely removed dabigatran and reduced by 98% rivaroxaban and by 92.3% apixaban concentrations (all p<0.05). After DOAC-Stop screening dRVVT remained prolonged in 34 (49.3%) patients (p<0.001), while dRVVT LA1/LA2 was abnormal in six (8.7%) subjects, with no association with DOAC concentrations at baseline and after DOAC-Stop. The APTT-LA screening test remained prolonged in five (7.2%) patients, while the APTT LA1/LA2 ratio was normal in those subjects. DOAC-Stop did not influence LA testing in APS patients.


Application of DOAC-Stop effectively reduced plasma DOAC concentrations leading to appropriate dRVVT results in up to 97% of VTE patients.

Keywords: antiphospholipid syndrome testing; direct oral anticoagulants (DOAC); DOAC-Stop; lupus anticoagulant


  • 1.

    Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009;7:1737–40.PubMedGoogle Scholar

  • 2.

    Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295–306.CrossrefPubMedGoogle Scholar

  • 3.

    Devreese KM, Ortel TL, Pengo V, de Laat B, Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH. J Thromb Haemost 2018;16:809–13.CrossrefPubMedGoogle Scholar

  • 4.

    Gardiner C, MacKie IJ, Malia RG, Jones DW, Winter M, Leeming D, et al. The importance of locally derived reference ranges and standardized calculation of dilute Russell’s viper venom time results in screening for lupus anticoagulant. Br J Haematol 2000;111:1230–5.PubMedCrossrefGoogle Scholar

  • 5.

    Asherson RA, Cervera R, deGroot PG, Erkan D, Boffa MC, Piette JC, et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 2003;12:530–4.CrossrefPubMedGoogle Scholar

  • 6.

    Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum 2002;46:1019–27.Google Scholar

  • 7.

    Lakos G. Interference in antiphospholipid antibody assays. Semin Thromb Hemost 2012;38:353–9.CrossrefWeb of SciencePubMedGoogle Scholar

  • 8.

    Depreter B, Devreese KM. Dilute Russell’s viper venom time reagents in lupus anticoagulant testing: a well-considered choice. Clin Chem Lab Med 2017;55:91–101.PubMedCrossrefWeb of ScienceGoogle Scholar

  • 9.

    Riva N, Lip GY. A new era for anticoagulation in atrial fibrillation. Which anticoagulant should we choose for long-term prevention of thromboembolic complications in patients with atrial fibrillation? Pol Arch Med Wewn 2012;122:45–53.Web of SciencePubMedGoogle Scholar

  • 10.

    Burnett AE, Mahan CE, Vazquez SR, Oertel LB, Garcia DA, Ansell J. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis 2016;41:206–32.PubMedWeb of ScienceCrossrefGoogle Scholar

  • 11.

    Hoxha A, Banzato A, Ruffatti A, Pengo V. Detection of lupus anticoagulant in the era of direct oral anticoagulants. Autoimmun Rev 2017;16:173–8.PubMedWeb of ScienceCrossrefGoogle Scholar

  • 12.

    Arachchillage DR, Mackie IJ, Efthymiou M, Isenberg DA, Machin SJ, Cohen H. Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome. J Thromb Haemost 2015;13:1264–73.CrossrefPubMedGoogle Scholar

  • 13.

    Bonar R, Favaloro EJ, Mohammed S, Pasalic L, Sioufi J, Marsden K. The effect of dabigatran on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples. Pathology 2015;47:355–64.PubMedWeb of ScienceCrossrefGoogle Scholar

  • 14.

    Bonar R, Favaloro EJ, Mohammed S, Ahuja M, Pasalic L, Sioufi J, et al. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples. Pathology 2016;48:60–71.Web of SciencePubMedCrossrefGoogle Scholar

  • 15.

    Helin TA, Lemponen M, Hjemdahl P, Rönquist-Nii Y, Lassila R, Joutsi-Korhonen L. From laboratory to clinical practice. Dabigatran effects on thrombin generation and coagulation in patient samples. Thromb Res 2015;136:154–60.CrossrefWeb of SciencePubMedGoogle Scholar

  • 16.

    Tripodi A, Braham S, Scimeca B, Moia M, Peyvandi F. How and when to measure anticoagulant effects of direct oral anticoagulants? Practical issues. Pol Arch Intern Med 2018;128:379–85.PubMedCrossrefGoogle Scholar

  • 17.

    Exner T, Michalopoulos N, Pearce J, Xavier R, Ahuja M. Simple method for removing DOACs from plasma samples. Thromb Res 2018;163:117–22.Web of ScienceCrossrefPubMedGoogle Scholar

  • 18.

    Tripodi A, de Groot PG, Pengo V. Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment. J Intern Med 2011;270:110–22.PubMedCrossrefWeb of ScienceGoogle Scholar

  • 19.

    Iwaniec T, Kaczor MP, Celińska-Löwenhoff M, Polański S, Musiał J. Identification of patients with triple antiphospholipid antibody positivity is platform and method independent. Pol Arch Med Wewn 2016;26:19–24.Google Scholar

  • 20.

    Faraoni D, Levy JH, Albaladejo P, Samama CM; Groupe d’Intérêt en Hémostase Périopératoire. Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants. Crit Care 2015;19:203.PubMedCrossrefGoogle Scholar

  • 21.

    Merriman E, Kaplan Z, Butler J, Malan E, Gan E, Tran H. Rivaroxaban and false positive lupus anticoagulant testing. Thromb Haemost 2011;105:385–6.CrossrefWeb of SciencePubMedGoogle Scholar

  • 22.

    Góralczyk T, Iwaniec T, Wypasek E, Undas A. False-positive lupus anticoagulant in patients receiving rivaroxaban: 24h since the last dose are needed to exclude antiphospholipid syndrome. Blood Coagul Fibrinolysis 2015;26:473–5.CrossrefGoogle Scholar

  • 23.

    Kopatz WF, Brinkman HJ, Meijers JC. Use of DOAC Stop for elimination of anticoagulants in the thrombin generation assay. Thromb Res 2018;170:97–101.PubMedCrossrefWeb of ScienceGoogle Scholar

  • 24.

    Hillarp A, Gustafsson KM, Faxälv L, Strandberg K, Baghaei F, Fagerberg Blixter I, et al. Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays. J Thromb Haemost 2014;12:1545–53.CrossrefPubMedWeb of ScienceGoogle Scholar

  • 25.

    Góralczyk T, Papuga-Szela E, Żuk J, Undas A. Measurement of apixaban concentrations in real–world clinical and laboratory settings: the first Polish experience. Pol Arch Intern Med 2018;128:324–6.Web of ScienceGoogle Scholar

About the article

Corresponding author: Anetta Undas, MD, PhD, Institute of Cardiology, Jagiellonian University Medical College and John Paul II Hospital, 80 Pradnicka St., 31-202 Krakow, Poland

Received: 2018-11-08

Accepted: 2019-01-07

Published Online: 2019-02-14

Published in Print: 2019-08-27

Funding Source: Jagiellonian University Medical College

Award identifier / Grant number: K/ZDS/007717

This work was supported by the Jagiellonian University Medical College (Funder id: 10.13039/100009045, grant number K/ZDS/007717, to A.U.).

Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), Volume 57, Issue 9, Pages 1374–1381, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm-2018-1197.

Export Citation

©2019 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

Magdalena Kopytek, Michał Ząbczyk, Krzysztof P. Malinowski, Anetta Undas, and Joanna Natorska
Clinical Chemistry and Laboratory Medicine (CCLM), 2019, Volume 0, Number 0
L. Slavik, J. Jacova, D. Friedecky, J. Ulehlova, Z. Tauber, J. Prochazkova, A. Hlusi, and M. Palova
Clinical and Applied Thrombosis/Hemostasis, 2019, Volume 25, Page 107602961987255
Emmanuel J. Favaloro, Grace Gilmore, Sandya Arunachalam, Soma Mohammed, and Ross Baker
Thrombosis Research, 2019, Volume 180, Page 10

Comments (0)

Please log in or register to comment.
Log in